PTC THERAPEUTICS INC (PTCT)       48.04  +0.68 (+1.44%)

48.04  +0.68 (+1.44%)

US69366J2006 - Common Stock - After market: 48.04 0 (0%)

PTC THERAPEUTICS INC48.04

NASDAQ:PTCT (2/3/2023, 7:03:22 PM)+0.68 (+1.44%)

After market: 48.04 0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 10-27 2022-10-27/amc Earnings (Next) 02-20 2023-02-20
Ins Owners 1.07% Inst Owners 105.35%
Market Cap 3.45B Shares 71.88M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 74.29
IPO 06-20 2013-06-20

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Growth Stock Screener

Find more growth stocks the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

PTCT Daily chart

Company Profile

PTC Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and commercialization of clinically differentiated medicines. The company is headquartered in South Plainfield, New Jersey and currently employs 1,252 full-time employees. The company went IPO on 2013-06-20. The Company’s portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases. The firm has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). The Company’s gene therapy platform focuses on the development of therapies for rare and debilitating diseases of the nervous system (CNS). The Company’s splicing platform focuses on the development of therapies for diseases, such as SMA, that involve regulation of messenger RNA (mRNA) splicing in the cell.

Company Info

PTC THERAPEUTICS INC

100 Corporate Ct

South Plainfield NEW JERSEY 07080

P: 19082227000.0

CEO: Stuart W. Peltz

Employees: 1252

Website: https://www.ptcbio.com/

PTCT News

News Image20 hours ago - PTC Therapeutics, Inc.PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company has been named the winner of 2023 EURORDIS Black Pearl Company Award for...

News Imagea day ago - PTC Therapeutics, Inc.PTC Therapeutics to Participate at Upcoming Investor Conference

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the following conference: SVB...

News Image12 days ago - PTC Therapeutics, Inc.NICE recomenda reembolso para Translarna™

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunciou hoje que o National Institute for Health and Care Excellence (NICE) publicou um Documento de...

News Image15 days ago - PTC Therapeutics, Inc.NICE recomienda el reembolso de Translarna™

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) anunció hoy que el National Institute for Health and Care Excellence (NICE) ha publicado un documento de...

News Image23 days ago - PTC Therapeutics, Inc.PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an...

News Image26 days ago - Market News VideoPTC Therapeutics Breaks Above 200-Day Moving Average - Bullish for PTCT

PTCT Twits

Here you can normally see the latest stock twits on PTCT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example